免疫球蛋白D
生物
B细胞受体
B细胞
幼稚B细胞
抗体
分子生物学
细胞
抗原
受体
免疫学
流式细胞术
免疫系统
T细胞
抗原提呈细胞
遗传学
作者
Sisi Li,Xiang Hu,Minjin Wang,Luoting Yu,Qi Zhang,Jing Xiao,Hong Zhao,Dong Zhou,Jinmei Li
摘要
Backgrounds Anti‐N‐methyl‐D‐aspartate receptor encephalitis (NMDAR‐E) is a severe autoimmune disorder characterized by prominent psychiatric symptoms. Although the role of NMDAR antibodies in the disease has been extensively studied, the phenotype of B cell subsets is still not fully understood. Methods We utilized single‐cell RNA sequencing, single‐cell B cell receptor sequencing (scBCR‐seq), bulk BCR sequencing, flow cytometry, and enzyme‐linked immunosorbent assay to analyze samples from both NMDAR‐E patients and control individuals. Results The cerebrospinal fluid (CSF) of NMDAR‐E patients showed significantly increased B cell counts, predominantly memory B (Bm) cells. CSF Bm cells in NMDAR‐E patients exhibited upregulated expression of differential expression genes (DEGs) associated with immune regulatory function ( TNFRSF13B and ITGB1 ), whereas peripheral B cells upregulated DEGs related to antigen presentation. Additionally, NMDAR‐E patients displayed higher levels of IgD − CD27 − double negative (DN) cells and DN3 cells in peripheral blood (PB). In vitro , DN1 cell subsets from NMDAR‐E patients differentiated into DN2 and DN3 cells, while CD27 + and/or IgD + B cells (non‐DN) differentiated into antibody‐secreting cells (ASCs) and DN cells. NR1‐IgG antibodies were found in B cell culture supernatants from patients. Differential expression of B cell IGHV genes in CSF and PB of NMDAR‐E patients suggests potential antigen class switching. Conclusion B cell subpopulations in the CSF and PB of NMDAR‐E patients exhibit distinct compositions and transcriptomic features. In vitro , non‐DN cells from NMDAR‐E can differentiate into DN cells and ASCs, potentially producing NR1‐IgG antibodies. Further research is necessary to investigate the potential contribution of DN cell subpopulations to NR1‐IgG antibody production.
科研通智能强力驱动
Strongly Powered by AbleSci AI